Echosens

May 13, 2022

Published by: Disclosures: Cusi reports receiving research support as principal investigator for the University of Florida from Cirius Therapeutics, Echosens, Inventiva, Novartis International, Novo Nordisk, Poxel and Zydus Pharmaceuticals, and serving as a consultant for Allergan, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Coherus BioSciences, Eli Lilly and Co., Fractyl Health, Hanmi Healthcare, Genentech, Gilead Sciences, Intercept Pharmaceuticals, Janssen Pharmaceuticals, Pfizer, Prosciento, Madrigal Pharmaceuticals and Novo Nordisk. Leffert reports no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio SAN DIEGO — In this video exclusive, Jonathan D. Leffert, MD, talks with Kenneth Cusi, MD, FACP, FACE, about the new American Association of Clinical Endocrinology nonalcoholic fatty liver disease guideline tailored for endocrinologists. Leffert is managing partner at North Texas Endocrine Center and past president of AACE. Cusi is chief of the division of endocrinology, diabetes and metabolism at the University of Florida in Gainsville. Both are Endocrine Today Editorial Board Members. They discuss the great prevalence of NAFLD among people with type 2 diabetes, how to diagnose NAFLD and medications on the horizon for treatment. Read more about